Oldie but goodie: Repurposing penicillin for tuberculosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed, 30 citations in OpenAlex.

1. Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial.American journal of respiratory and critical care medicine · 2022
   Trial
2. Mycobacteria susceptibility to epetraborole: how far can it go?The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2025
   Article
3. Case Commentary: Dual β-lactam as part of regimen to treatAntimicrobial agents and chemotherapy · 2024
   Article
4. Identification of β-Lactams Active againstACS infectious diseases · 2022
   Article
5. Penicillin Binding Proteins and β-Lactamases of Mycobacterium tuberculosis: Reexamination of the Historical Paradigm.mSphere · 2022
   Article
6. Collateral Sensitivity to β-Lactam Drugs in Drug-Resistant Tuberculosis Is Driven by the Transcriptional Wiring of BlaI Operon Genes.mSphere · 2021
   Article
7. Investigating β-Lactam Drug Targets inACS infectious diseases · 2021
   Article
8. Assessment of carbapenems in a mouse model of Mycobacterium tuberculosis infection.PloS one · 2021
   Article
9. Revisiting the β-Lactams for Tuberculosis Therapy with a Compound-Compound Synthetic Lethality Approach.Antimicrobial agents and chemotherapy · 2019
   Article
10. Revisiting Anti-tuberculosis Therapeutic Strategies That Target the Peptidoglycan Structure and Synthesis.Frontiers in microbiology · 2019
    Review
11. Pharmacokinetics of β-Lactam Antibiotics: Clues from the Past To Help Discover Long-Acting Oral Drugs in the Future.ACS infectious diseases · 2018
    Article
12. Have we realized the full potential of β-lactams for treating drug-resistant TB?IUBMB life · 2018
    Review
13. Whole genome SNP analysis suggests unique virulence factor differences of the Beijing and Manila families of Mycobacterium tuberculosis found in Hawaii.PloS one · 2018
    Article
14. Mutation in an Unannotated Protein Confers Carbapenem Resistance in Mycobacterium tuberculosis.Antimicrobial agents and chemotherapy · 2017
    Article
15. New agents for the treatment of drug-resistant Mycobacterium tuberculosis.Advanced drug delivery reviews · 2016
    Review
16. Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics.EBioMedicine · 2016
    Article
17. Mechanism of MenE inhibition by acyl-adenylate analogues and discovery of novel antibacterial agents.Biochemistry · 2015
    Article
18. Combinations of β-Lactam Antibiotics Currently in Clinical Trials Are Efficacious in a DHP-I-Deficient Mouse Model of Tuberculosis Infection.Antimicrobial agents and chemotherapy · 2015
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as